As an academic medical center, research is core to the Columbia University Medical Center’s mission. Our physicians are pioneers investigating alternative treatment solutions for valve disease. Our center serves as the national principal investigation site for the PARTNER Trial, the clinical study which led to the FDA’s approval of TAVR in the U.S. in November of 2011. Today, we are investigators for the PARTNER II Trial which is evaluating TAVR for an expanded patient population. We are also investigators for the COAPT Trial*, which is examining the safety and effectiveness of a minimally invasive catheter-based treatment for mitral valve regurgitation. Additionally, we continue to be involved, as we have for many years, in several clinical trials examining new and innovative minimally invasive surgical treatments for heart valve disease.
*Columbia University receives royalties from Abbott Vascular for sale of the MitraClip.